- Home
- SAVA vs CGO Comparison
SAVA vs CGO Comparison
Compare SAVA & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- CGO
- Stock Information
- Founded
- SAVA 1998
- CGO 2004
- Country
- SAVA United States
- CGO United States
- Employees
- SAVA N/A
- CGO N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- CGO Investment Managers
- Sector
- SAVA Health Care
- CGO Finance
- Exchange
- SAVA Nasdaq
- CGO Nasdaq
- Market Cap
- SAVA 102.4M
- CGO 114.2M
- IPO Year
- SAVA N/A
- CGO N/A
- Fundamental
- Price
- SAVA $2.34
- CGO $11.75
- Analyst Decision
- SAVA Hold
- CGO
- Analyst Count
- SAVA 1
- CGO 0
- Target Price
- SAVA $2.00
- CGO N/A
- AVG Volume (30 Days)
- SAVA 867.7K
- CGO 34.7K
- Earning Date
- SAVA 08-14-2025
- CGO 01-01-0001
- Dividend Yield
- SAVA N/A
- CGO 9.25%
- EPS Growth
- SAVA N/A
- CGO N/A
- EPS
- SAVA N/A
- CGO N/A
- Revenue
- SAVA N/A
- CGO N/A
- Revenue This Year
- SAVA N/A
- CGO N/A
- Revenue Next Year
- SAVA N/A
- CGO N/A
- P/E Ratio
- SAVA N/A
- CGO N/A
- Revenue Growth
- SAVA N/A
- CGO N/A
- 52 Week Low
- SAVA $1.15
- CGO $7.90
- 52 Week High
- SAVA $33.98
- CGO $10.93
- Technical
- Relative Strength Index (RSI)
- SAVA 54.06
- CGO 55.87
- Support Level
- SAVA $2.20
- CGO $11.49
- Resistance Level
- SAVA $2.43
- CGO $11.87
- Average True Range (ATR)
- SAVA 0.17
- CGO 0.15
- MACD
- SAVA -0.00
- CGO 0.01
- Stochastic Oscillator
- SAVA 60.42
- CGO 78.95
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.